A Multicenter, Randomized, Open-label, Active-drug Controlled Study to evaluate efficacy and safety of Sitafloxacin in patients with Community-acquired Pneumonia in China

Trial Profile

A Multicenter, Randomized, Open-label, Active-drug Controlled Study to evaluate efficacy and safety of Sitafloxacin in patients with Community-acquired Pneumonia in China

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2015

At a glance

  • Drugs Sitafloxacin (Primary) ; Moxifloxacin
  • Indications Community-acquired pneumonia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top